Condition: Gynecological Tumors · Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), a enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of antibodies to specifically target tumour cells with the highly potent killing activity of drugs with payloads too toxic for systemic administration. This is a Phase 2 study to evaluate the efficacy,and safety of TQB2102 for injection in recurrent/metastatic advanced gynecological tumors.
This description comes directly from the study's public registry record.
Jundong Li, Master · 13602859865 · lijd@sysucc.org.cn
Yang Sun, Doctor · 15959028989 · doctorsunyang@sina.com
Always discuss trial participation with your own doctor first.
| Cancer Hospital Chinise Academy of Medical Sciences | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Chongqing University Cancer Hospital | Chongqing, Chongqing Municipality, China | Not Yet Recruiting |
| Fujian Provincial Maternal and Child Health Hospital | Fuzhou, Fujian, China | Not Yet Recruiting |
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| GanSu Cancer Hospital | Lanzhou, Gansu, China | Not Yet Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Guangzhou Women and Children's Medical Center | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Meizhou peoples Hospital | Meizhou, Guangdong, China | Not Yet Recruiting |
| Affiliated Qingyuan Hospital, Guangzhou Medical University,Qingyuan People's Hospital | Qingyuan, Guangdong, China | Recruiting |
| Affiliated Qingyuan Hospital,Guangzhou Medical University,Qingyuan People's Hospital | Qingyuan, Guangdong, China | Not Yet Recruiting |
| Guangxi Medical University Cancer Hospital | Nanning, Guangxi, China | Not Yet Recruiting |
| The Fourth Hospital of Hebei Medical University | Shijiazhuang, Hebei, China | Not Yet Recruiting |
+ 19 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06798207